Re-Evaluating Risks and Benefits in Human Subjects Research
By Jonathan Kahn, Biopolitical Times guest contributor
| 05. 25. 2011
Modern bioethics is grounded in four basic principles: respect for persons (i.e. autonomy), beneficence, nonmalificence and justice. In a recent presentation at the 2011 ELSI Congress, "Exploring the ELSI Universe," Malia Fullerton, a professor in the Department of Bioethics & Humanities at the University of Washington School of Medicine, noted that "respect for persons" and "beneficence" have come to be the preeminent values in bioethical review of human subjects studies, particularly in the context of IRB review. Respect for persons typically manifests in a concern for informed consent, and beneficence in a concern for weighing the potential harms and benefits of research. Fullerton argued that a more balanced consideration of the other values, particularly justice and a concern for persons not just in terms of consent but in terms of dignity, needed to be incorporated into such review.
This got me to thinking about these concepts and their deployment in current biomedical research. Beneficence has often been cast in terms of balancing costs and benefits, as though it were simply a utilitarian calculus. However, in the context of...
Related Articles
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
By Philip Ball , Nature | 06.17.2026
Our genomes are full of mutations that have the potential to damage our health or even kill us. Yet most of them rarely cause problems. Why? It’s partly thanks to a family of proteins that mask, or ‘buffer’, the ill...
By Philip Ball, Quanta Magazine | 06.18.2026
Since its molecular structure was deduced in the 1950s, DNA has been hailed by many biologists as the secret of life. They’ve read and studied the information stored in the DNA found in the cells of living organisms, known as...
By Arche Noah, GMWatch | 06.17.2026
The European Parliament has voted for a wide-reaching deregulation of New Genomic Techniques (NGTs). There was no majority for amendments stopping patents on conventionally classically bred plants or NGT plants. “Today’s vote is a missed opportunity to protect Europe’s farmers...